June 12, 2017August 24, 2022
Diplomat Pharmacy Begins Dispensing Kevzara to Treat Rheumatoid Arthritis

Diplomat Pharmacy has begun filling prescriptions for Kevzara (sarilumab) for patients with moderate to severe rheumatoid arthritis (RA). The announcement comes after the U.S. Food and Drug ... Read more
June 7, 2017June 7, 2017
Filgotinib Improves RA Patient Outcomes When Methotrexate Is Inadequate, Study Suggests

Active rheumatoid arthritis (RA) patients whose response to methotrexate (MTX) therapy was insufficient showed improvement when MTX was combined with filgotinib, an investigational JAK–1 inhibitor, according ... Read more
June 5, 2017June 5, 2017
EMA Accepts Humira and Remicade Biosimilars for Regulatory Review

The European Medicines Agency (EMA) has accepted a marketing authorization application from generic pharmaceuticals developer Sandoz for the review of biosimilars for AbbVie’s Humira (adalimumab) and Janssen’s Remicade (infliximab), ... Read more
June 2, 2017June 2, 2017
DMARDs Triple Therapy Provides Better Cost-Effective First Line Strategy for RA, Study Finds

Results of a recent study showed that biological therapy regimens, such as Enbrel (etanercept), Humira (adalimumab), ‎Remicade (infliximab), ‎Simponi (golimumab), or ‎Cimzia (certolizumab), are less cost-effective ... Read more
May 23, 2017May 23, 2017
Kevzara Approved by FDA for Treatment of RA in Adults Who Don’t Respond to DMARDs

Kevzara (sarilumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with moderate to severely active rheumatoid arthritis ... Read more

January 25, 2017January 25, 2017

ACR Writes Congressional Leaders About Healthcare Priorities for Rheumatic Diseases

News

As the 115th U.S. Congress considers potential healthcare reform, the American College of Rheumatology (ACR) sent a letter to congressional leaders to ensure that proposals will protect and promote access ... Read more

January 23, 2017January 23, 2017

Targeting SCIMP Protein Shows Potential in Inflammatory Diseases Like RA

News

The ability to reduce or “switch off” inflammation may be possible thanks to a new discovery made by researchers at the University of Queensland (UQ) in Australia. They found that a ... Read more

January 20, 2017January 20, 2017

14.4M Euros Awarded to European Consortium to Develop Therapies for Inflammatory Diseases

News, rheumatoid arthritis

Based on the prevalence of chronic inflammatory diseases worldwide, an affiliation of nine European countries, including academic and industry partners, has been awarded 14.4 million euros (around $15.3 million U.S.) to ... Read more

January 18, 2017January 18, 2017

Review Period for Eli Lilly’s RA Therapy Baricitinib Extended by FDA

News, rheumatoid arthritis

The U.S. Food and Drug Administration (FDA) has extended the review period for a new drug application (NDA) for Eli Lilly’s investigational treatment baricitinib for rheumatoid arthritis (RA). The announcement was ... Read more

January 16, 2017January 16, 2017

Crafoord Prize Honors 3 for Discoveries in Regulatory T-cells That Control Immune Responses

News

This year’s Crafoord Prize in Polyarthritis was awarded to three researchers in the field of immunology for discoveries made in immune regulatory T-cells, a subpopulation of T-cells that modulate the immune system, maintain tolerance to ... Read more

January 16, 2017January 16, 2017

RA Treatment with TNF Inhibitors Greatly Decreases Heart Attack Risk, UK Study Finds

News

The risk of heart attack associated with rheumatoid arthritis (RA) may decrease by nearly half when TNF inhibitors (TNFi) are part of the treatment, according to new research conducted at ... Read more

January 11, 2017January 11, 2017

Phase 2 Study in Brazil to Test Efficacy of IL-6 Antibody, Possible Low-Cost Therapy Option

News, rheumatoid arthritis

Brazilian regulatory authorities have approved a Phase 2 clinical trial to evaluate gerilimzumab, a new antibody against the IL-6 cytokine, as a treatment for rheumatoid arthritis (RA). The protocol was developed specifically for patients ... Read more

January 9, 2017January 9, 2017

Pfizer’s Alternative to Humira Proves Effective in Rheumatoid-arthritis Trial

News

A therapy that Pfizer developed as a cheaper alternative to Humira (adalimumab) has shown it is as effective as Humira in treating rheumatoid arthritis. The results came in a Phase 3 trial of PF-06410293, ... Read more

January 6, 2017January 6, 2017

Baricitinib Closer to Obtaining European Approval for Treatment of Rheumatoid Arthritis

News, rheumatoid arthritis

European regulators have taken a key step toward approving baricitinib to treat those with moderate to severe rheumatoid arthritis (RA). The European Medicines Agency’s Committee for Medicinal Products for Human Use ... Read more

January 4, 2017January 4, 2017

4-Year Delay in Diagnosis Common for Rheumatoid Arthritis in US, Patient Survey Finds

News, rheumatoid arthritis

In a recent survey, rheumatoid arthritis (RA) patients reported having six or more symptoms that affect multiple parts of the body, and of waiting an average of four years before being ... Read more